Literature DB >> 7672512

Endothelin receptors and calcium signaling.

D M Pollock1, T L Keith, R F Highsmith.   

Abstract

Endothelin (ET) is a potent vasoactive peptide produced by endothelial cells that elicits prolonged constriction in most smooth muscle preparations and dilation in others. Of three isopeptides, ET-1 is the only form constitutively released and may modulate vascular tone via binding to one of several receptor subtypes in smooth muscle. Activation of the ETA receptor is associated with pronounced vasoconstriction whereas ETB receptor occupation is linked to vasodilation. In addition, other subtypes of the ETB receptor exist, one mediating vasodilation (ETB1) and the other eliciting constriction (ETB2). An additional receptor subtype, ETC, has been identified although its physiological significance is uncertain. Distribution of these receptors varies between species and among tissue types, although it has been generally observed that ETA receptors predominate in arterial vessels whereas ETB receptors predominate on the low pressure side of the circulation. In vascular smooth muscle, an increase in intracellular Ca2+ is a common feature occurring after activation of all receptor subtypes. Upon binding of ET-1 to ETA, phospholipase C is activated and inositol triphosphate is generated. Ca2+ is then released from intracellular stores accompanied by the influx of extracellular Ca2+ and activation of the contractile machinery. The precise mechanism by which ET-1 affects intracellular Ca2+ regulation is not fully understood, but most likely involves multiple ion channels, protein kinases, and other intracellular mediators. The events coupled to non-ETA receptor signaling are poorly understood.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7672512     DOI: 10.1096/fasebj.9.12.7672512

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  54 in total

1.  Two-photon imaging of endothelin-1-mediated intracellular Ca(2+) handling in smooth muscle cells of rat renal resistance arteries.

Authors:  Oleg Palygin; Bradley Miller; Daria V Ilatovskaya; Andrey Sorokin; Alexander Staruschenko
Journal:  Life Sci       Date:  2015-12-10       Impact factor: 5.037

2.  Acute blockade by endothelin-1 of haemodynamic insulin action in rats.

Authors:  R M Ross; C M Kolka; S Rattigan; M G Clark
Journal:  Diabetologia       Date:  2006-12-23       Impact factor: 10.122

Review 3.  Mechanisms of drug combinations: interaction and network perspectives.

Authors:  Jia Jia; Feng Zhu; Xiaohua Ma; Zhiwei Cao; Zhiwei W Cao; Yixue Li; Yixue X Li; Yu Zong Chen
Journal:  Nat Rev Drug Discov       Date:  2009-02       Impact factor: 84.694

4.  Cryopreservation of vascular tissues.

Authors:  Else Müller-Schweinitzer
Journal:  Organogenesis       Date:  2009-07       Impact factor: 2.500

5.  Role of statins in cerebral vasospasm.

Authors:  T Sugawara; R Ayer; J H Zhang
Journal:  Acta Neurochir Suppl       Date:  2008

Review 6.  Endothelin receptors: what's new and what do we need to know?

Authors:  Stephanie W Watts
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-11-11       Impact factor: 3.619

7.  The mechanism of cryoinjury: In vitro studies on human internal mammary arteries.

Authors:  E Müller-Schweinitzer; W Brett; H R Zerkowski; W E Haefeli
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

Review 8.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 9.  Endothelial dysfunction: a strategic target in the treatment of hypertension?

Authors:  Eva H C Tang; Paul M Vanhoutte
Journal:  Pflugers Arch       Date:  2010-02-02       Impact factor: 3.657

10.  Endothelin ET(B) receptors in arteries and veins: multiple actions in the vein.

Authors:  Nathan R Tykocki; Cheryl E Gariepy; Stephanie W Watts
Journal:  J Pharmacol Exp Ther       Date:  2009-03-18       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.